These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36151444)

  • 1. Clinical Ocular Exposure Extrapolation for Ophthalmic Solutions Using PBPK Modeling and Simulation.
    Le Merdy M; AlQaraghuli F; Tan ML; Walenga R; Babiskin A; Zhao L; Lukacova V
    Pharm Res; 2023 Feb; 40(2):431-447. PubMed ID: 36151444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular Physiologically Based Pharmacokinetic Modeling for Ointment Formulations.
    Le Merdy M; Spires J; Lukacova V; Tan ML; Babiskin A; Xu X; Zhao L; Bolger MB
    Pharm Res; 2020 Nov; 37(12):245. PubMed ID: 33215336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically Based Pharmacokinetic Model to Support Ophthalmic Suspension Product Development.
    Le Merdy M; Tan ML; Babiskin A; Zhao L
    AAPS J; 2020 Jan; 22(2):26. PubMed ID: 31907674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of Mechanistic Ocular Absorption Modeling and Simulation to Understand the Impact of Formulation Properties on Ophthalmic Bioavailability in Rabbits: a Case Study Using Dexamethasone Suspension.
    Le Merdy M; Fan J; Bolger MB; Lukacova V; Spires J; Tsakalozou E; Patel V; Xu L; Stewart S; Chockalingam A; Narayanasamy S; Rouse R; Matta M; Babiskin A; Kozak D; Choi S; Zhang L; Lionberger R; Zhao L
    AAPS J; 2019 May; 21(4):65. PubMed ID: 31111305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocol for evaluation of topical ophthalmic drug products in different compartments of fresh eye tissues in a rabbit model.
    Chockalingam A; Xu L; Stewart S; LeMerdy M; Tsakalozou E; Fan J; Patel V; Rouse R
    J Pharmacol Toxicol Methods; 2019; 96():9-14. PubMed ID: 30552958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.
    Mather R; Karenchak LM; Romanowski EG; Kowalski RP
    Am J Ophthalmol; 2002 Apr; 133(4):463-6. PubMed ID: 11931779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational Model of In Vivo Corneal Pharmacokinetics and Pharmacodynamics of Topically Administered Ophthalmic Drug Products.
    German C; Chen Z; Przekwas A; Walenga R; Babiskin A; Zhao L; Fan J; Tan ML
    Pharm Res; 2023 Apr; 40(4):961-975. PubMed ID: 36959411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically Based Pharmacokinetic Modeling and Clinical Extrapolation for Topical Application of Pilocarpine on Eyelids: A Comprehensive Study.
    Lin J; Bu F; Wu D; Jiang P; He Q; Yang D; Zhu X; Wang Y; Xiang X
    J Pharm Sci; 2024 Jun; ():. PubMed ID: 38857643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eye drops and eye gels of levofloxacin: comparison of ocular absorption characterizations and therapeutic effects in the treatment of bacterial keratitis in rabbits.
    Li G; Xu L; Jiang M; Wu X
    Drug Dev Ind Pharm; 2020 Apr; 46(4):673-681. PubMed ID: 32233932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
    Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
    Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of moxifloxacin and levofloxacin in an epithelial disorder model using cultured rabbit corneal epithelial cell sheets.
    Miyake T; Ito N; Tajima K; Goto H; Furukawa T
    Graefes Arch Clin Exp Ophthalmol; 2012 Jul; 250(7):1035-41. PubMed ID: 22282216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits.
    Bussing D; K Shah D
    J Pharmacokinet Pharmacodyn; 2020 Dec; 47(6):597-612. PubMed ID: 32876799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
    Proksch JW; Ward KW
    J Ocul Pharmacol Ther; 2010 Oct; 26(5):449-58. PubMed ID: 20874668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically based ocular pharmacokinetic modeling using computational methods.
    Missel PJ; Sarangapani R
    Drug Discov Today; 2019 Aug; 24(8):1551-1563. PubMed ID: 31319151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General Pharmacokinetic Model for Topically Administered Ocular Drug Dosage Forms.
    Deng F; Ranta VP; Kidron H; Urtti A
    Pharm Res; 2016 Nov; 33(11):2680-90. PubMed ID: 27431864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of lipid peroxidation and electron microscopic survey of maturation stages during human cataractogenesis: pharmacokinetic assay of Can-C N-acetylcarnosine prodrug lubricant eye drops for cataract prevention.
    Babizhayev MA
    Drugs R D; 2005; 6(6):345-69. PubMed ID: 16274259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calculation of AQCmax: comparison of five ophthalmic fluoroquinolone solutions*.
    Fukuda M; Sasaki H
    Curr Med Res Opin; 2008 Dec; 24(12):3479-86. PubMed ID: 19032129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Drug Concentrations in Human Aqueous Humor after the Administration of 0.3% Gatifloxacin Ophthalmic Gel, 0.3% Gatifloxacin and 0.5% Levofloxacin Ophthalmic Solutions.
    Ding W; Ni W; Chen H; Yuan J; Huang X; Zhang Z; Wang Y; Yu Y; Yao K
    Int J Med Sci; 2015; 12(6):517-23. PubMed ID: 26078713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of Azithromycin, Levofloxacin, and Ofloxacin in Rabbit Extraocular Tissues After Ophthalmic Administration.
    Sakai T; Shinno K; Kurata M; Kawamura A
    Ophthalmol Ther; 2019 Dec; 8(4):511-517. PubMed ID: 31372937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
    Kowalski RP; Dhaliwal DK; Karenchak LM; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
    Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.